Physician profile
Aisha Shareef
NPI 1669632964
$24,896.81
in general payments reported to CMS, 2019-2025
69 companies · $3,904 in 2025
The $3,904 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,967 · 2020: $2,240 · 2021: $2,579 · 2022: $3,206 · 2023: $3,897 · 2024: $4,104 · 2025: $3,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $28.40 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,858.09 |
| Education | $28.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,608.97 | 2019-2025 | |
| Biogen, INC. | $1,758.49 | 2020-2025 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $1,487.11 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Mdd US Operations, LLC | $1,277.90 | 2019-2025 | Apokyn, Apokyn |
| Ucb, INC. | $990.76 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Genzyme Corporation | $947.01 | 2019-2025 | |
| Lilly USA, LLC | $810.91 | 2019-2025 | Amyvid, Reyvow, Emgality |
| Teva Pharmaceuticals USA, INC. | $774.42 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $766.15 | 2019-2025 | Mavenclad, Mavenclad |
| Lundbeck LLC | $650.35 | 2019-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $615.83 | 2020-2025 | Valtoco |
| Pfizer INC. | $577.23 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $558.50 | 2019-2022 | |
| Sk Life Science, INC. | $551.06 | 2022-2025 | Xcopri |
| Argenx US, INC. | $515.25 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $482.65 | 2019-2025 | Ultomiris, Soliris |
| Amneal Pharmaceuticals LLC | $455.19 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Neurocrine Biosciences, INC. | $449.39 | 2019-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $433.33 | 2022-2025 | Zeposia |
| Genentech USA, INC. | $424.16 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Amgen INC. | $423.98 | 2019-2022 | |
| Eisai INC. | $394.50 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $381.91 | 2019-2023 | |
| Banner Life Sciences, LLC | $374.54 | 2022-2024 | |
| Livanova USA, INC. | $319.60 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Csl Behring | $314.56 | 2020-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $272.79 | 2019-2025 | Nuplazid |
| Corium, LLC | $267.72 | 2022-2023 | Adlarity |
| Catalyst Pharmaceuticals, INC. | $265.89 | 2023-2025 | Fycompa |
| Acorda Therapeutics, INC | $243.73 | 2019-2023 | Inbrija, Ampyra |
| Takeda Pharmaceuticals U.S.A., INC. | $236.94 | 2022-2025 | Hyqvia, Gammagard |
| Jazz Pharmaceuticals INC. | $233.06 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $224.35 | 2022 | |
| Vanda Pharmaceuticals INC. | $200.03 | 2024-2025 | Ponvory |
| Janssen Pharmaceuticals, INC | $181.79 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $161.27 | 2021 | |
| Kyowa Kirin, INC. | $144.32 | 2021-2023 | Nourianz |
| Avanir Pharmaceuticals, INC. | $130.56 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.70 | 2022 | |
| Tanabe Pharma America, INC. | $117.56 | 2021-2025 | Radicava |
| Supernus Pharmaceuticals, INC. | $111.54 | 2021-2022 | |
| Allergan, INC. | $109.61 | 2020-2021 | |
| Chiesi USA, INC. | $107.24 | 2020-2025 | Cleviprex |
| Ani Pharmaceuticals, INC. | $101.16 | 2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $94.33 | 2023-2024 | Rexulti, Nuedexta |
| Ekos Corporation | $93.33 | 2019 | |
| Impel Pharmaceuticals LLC | $93.20 | 2024-2025 | Trudhesa |
| Tg Therapeutics, INC. | $90.91 | 2023-2025 | |
| Cycle Pharmaceuticals INC | $90.82 | 2025 | Bafiertam, Tascenso Odt |
| Adamas Pharmaceuticals, INC. | $79.00 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $77.10 | 2022-2025 | Wainua |
| Abbott Laboratories | $70.35 | 2019-2022 | |
| Medtronic USA, INC. | $66.48 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $63.53 | 2023 | Aptiom |
| Greenwich Biosciences, INC. | $61.52 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $54.11 | 2023 | Trudhesa |
| Octapharma USA, INC. | $49.32 | 2024-2025 | Panzyga |
| Bausch Health US, LLC | $41.94 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $39.66 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $39.44 | 2020-2025 | Dysport |
| Ceribell, INC. | $35.69 | 2023-2025 | Ceribell Rapid Response Eeg, Pocket Eeg Device |
| Stryker Corporation | $34.15 | 2025 | Spinejack |
| Axsome Therapeutics, INC. | $28.24 | 2025 | Symbravo |
| Almatica Pharma LLC | $26.85 | 2021 | |
| Janssen Biotech, INC. | $21.52 | 2025 | |
| Boston Scientific Corporation | $20.22 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.72 | 2024 | Onpattro |
| Merz Pharmaceuticals, LLC | $16.88 | 2025 | Xeomin |
| Zyla Life Sciences, INC. | $12.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aisha Shareef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.